<?xml version='1.0' encoding='iso-8859-1'?>
<newsitem date="1996-10-28" id="root" itemid="146853" xml:lang="en">
<title>USA: Immune Response offers 2.2 mln shrs $6.50.</title>
<headline>Immune Response offers 2.2 mln shrs $6.50.</headline>
<dateline>CARLSBAD, Calif. 1996-10-28</dateline>
<text>
<p>Immune Response Corp's 2.2 million share public offering of common stock was priced at $6.50 per share, the company said.</p>
<p>Bayer AG unit Bayer Corp has indicated it will purchase 615,400 shares.  All of the shares are being sold by the company.  Immune Response, a biopharmaceutical company, has granted the underwriters an option to purchase an additional 330,000 shares to cover over-allotments.</p>
<p>The offering is being managed by Hanifen, Imhoff Inc and Cruttenden Roth Inc.</p>
<p>-- New York Newsdesk 212-859-1610</p>
</text>
<copyright>(c) Reuters Limited 1996</copyright>
<metadata>
<dc element="dc.date.created" value="1996-10-28" />
<dc element="dc.publisher" value="Reuters Holdings Plc" />
<dc element="dc.date.published" value="1996-10-28" />
<dc element="dc.source" value="Reuters" />
<dc element="dc.creator.location" value="CARLSBAD, Calif." />
<dc element="dc.creator.location.country.name" value="USA" />
<dc element="dc.source" value="Reuters" />
</metadata>
</newsitem>